Sanofi (SNY) Cost of Revenue (2009 - 2026)

Sanofi has reported Cost of Revenue for 18 years, with the latest figure at $3.5 billion in Q2 2026.

• Quarterly Cost of Revenue rose 3.54% year-over-year to $3.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $33.2 billion (up 35.32% YoY) and the FY2025 annual result came in at $15.2 billion, up 7.65% from the prior year.
• Cost of Revenue eased to $3.5 billion in Q2 2026 per SNY's latest filing, from $3.7 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $15.2 billion in Q4 2025 and troughed at $3.0 billion in Q1 2025.
• A 5-year average of $6.3 billion and a median of $3.6 billion in 2026 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue decreased 9.31% in 2024, then surged 170.06% in 2025.
• Over 5 years, Cost of Revenue stood at $14.0 billion in 2022, then dropped by 2.76% to $13.6 billion in 2023, then grew by 3.86% to $14.1 billion in 2024, then rose by 7.65% to $15.2 billion in 2025, then plunged by 76.91% to $3.5 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.5 billion, $3.7 billion, and $15.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.